We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Annual report should be released any day now
I want to agree with you on the confidence in new leadership and strategy as well as Presentation well received part. I had topped up as well after watching the interview. Addressable market is enormous and as mentioned hard to predict exact size because the boundaries of the application of ONC ImmunoInsights are ever expanding. Perhaps interest rate developments just coincide with the news coming from ONC. Maybe the combination is doing the trick.....in any case we have a highly motovated leadership that knows Big Pharma and Biotech and have been hired for their ability to scale ONC from single digit mio revenue to multi-digit revenue company.
Commercial focus
Investors in mind
Bleeding edge of Innovation (Luminex and AI....)
Leader in industry
Hardly any comparable comüetition
MSAs with Big Pharma companies
Established Sales Team
Time to crush it!
(Probably another 3-5 year hold..... then i may consider retirement....please!!!)
Faith in new CEO/ new plan? Presentations and interview well received?
I am doubtful about interest rates having an impact at all at this point.
It was oversold as if it would collapse, which clearly is not the case. They are back fighting with a vengeance !!
Annual resuls will be a disaster in my view (baked in and more), but I think the new plan will carry more weight that the past failures, so could well continue to move up. The potential for this business is enormous.
Nice pop in the SP. Again could be due to the news around interest rates.
My take is that as inflation goes down and Central banks start mulling the decrease in interest rates we will see a natural lift in the market. For ONC specifocally the coming Report will be interesting as there should be a good foundation of revenue stemming from the following 3 partnerships alone: Biodesix, Freenome and Siemens Healthineers, not to speak of all other business we have not been exposed to as much.
I have a feeling that similar to how fast the SP crashed, we may see it go back up again.
Super excited about the prospects.
Great find. The one day i didnt scan the market for news. ^^ have been waiting for this interview for a bit. And absolutely confident that we will see this business realise revenue from all the contracta they have landed to date and new ones they are landing. I am holding tight man!
Courtesy brummy_git over at ADVFN:
https://www.youtube.com/watch?v=hOsXNm-r3LQ
Worth watching. I feel this has been a big reset and looking forward to results going forward!
Well, clearly something going on!!
A real investor making a genuine punt + FOMO?; or just pump&dump?; or insider info leaked to analysts, friends&family? TBC, only time will tell.
However, if you believe in the new strategic focus and that they can execute then the share is clearly hugely undervalued, especially if you look at the prospects for high margin revenue.
There seems to have a small relly in a few small caps incl ONC on AIM....could be inflation related with the sharp drop from recent readings (4.6%)
Seems unlikely to be random. Over the last few weeks we have not seen more than 3-4 trades a day. 10 folding that today. Guessing investors know about something
Insider info - news coming?
Or just speculation?
Feels random.
Nice little boost there for the struggling SP. 22% from nearly nothing makes it nearly something. Lets keep going. 22 trades with highest trade at 14k....seems like it doesnt take much to move the needle here.
No doubt they will need to rationalise it all. Reflect the revamped strategy and provide some forward looking statements. We may learn a nice thing or two from commercial successes. Last TU was more than 6months ago...
Would be nice to get the annual results out of the way!!! It's going to be a car crash, but I'm positive about the future given the strategic reset.
Just watched the recording. Like you mentioned there seems to be a lot of untapped potential for ImmunoInsights. Slim competition and a big addressable market especially when the Big Pharmas/and Biopharmas etc are seeing value of such antibody profiling services during the CRO cycles. I think that this address to the investors was important to win back some confidence and I thank Martin for delivering the message to the investors that a more predictable growth and revenue is needed an this is being implemented now too. I hope this also means that we can get some guidance in the coming reports on what to expect. You see these days, much of what is being invested is based on future growth. And without any reliable prediction or forecast all this goes out the window. Hence why ONC trades at these levels. Growth is baked in to the current SP at the most conservative level...
Looking forward to the year ahead with this business.
Thanks Doc....I will review the recording too when I get a chance today. It all sounds so promising. Oh how I wish today was my first day to know ONC. What an SP indeed. Similar to yourself I was bought in with Early-CDT, first but around the ECLS study. I think that is why the asset sale was a bit of a punch to the gut. But it seems like we should be on the up soon again.
You can watch a recording on the Investor meet Company website. I have just done the same, had to be somewhere else yesterday.
In anutshell: unique IP with little competition, technology ripe for exploitation, a credible team and strategy, including renewed commercial focus/approach and new focus areas, like diabetes and neuroscience. Potentially a lot more value to be realised. They can actually potentially do a hell of a lot more than I thought, having originally bought in due to EarlyCDT only.
Now we need solid financial progress going forward. Past financial performance leaves a lot to be desired, but that's also why the share price is so low. They will also be looking to create more stable, recurring income streams, which is good for stability and investor nerves in particular!!
Has anyone here joined the investor meet yesterday? I was going to but ended up on a flight at the same time. Would be curious to hear what people thought.
No RNS with results today(yet), so I would conclude this is only an intro of new team and the new/adjusted strategic direction. That's OK, I think. Results will not be great, I am almost certain of that, but already baked into the sp.
Expect results tomorrow then? Otherwise wtf is the point!
Usual caveats
Trek
...on 25 october is a very good thing and will hopefully build trust in the new team & strategy! (See RNS for details)
Difficult to say, could also reach 10p until we start seeing financial progress tbh. Almost random until we have more news. Having said that, most investors, including the large investors, are holding on to their shares; very thin trading.
I am also very optimistic.
The large investors are no doubt waiting patiently for a corporate takeover/exit. They paid a lot more for their shares than the current price, so lowball offers should be rejected.
I am actually for once super optimistic. Think we must have hit the bottom.
https://www. v o x markets.co.uk/articles/oncimmune-shifts-strategy-to-accelerate-commercial-expansion-871f174/
I agree, everything sounds very sensible. If they are at 20-30% capacity then I would be more than happy, as I think they have been running at a lot less during the first half of the financial year.
I like the clarity and focus. This is all about ramping up the numbers.
The proof is in the pudding - let's see the numbers.
It may be another year before we see real, significant progress, but that's OK! The share price will then follow suit!!
Sorry....CAPEX reduced due to sale of assets to Biodesix and Freenome whilst longer term revenue secured at least for next couple of years. OPEX I think overall down due tonlower overheads. Not sure how the employee salaries play into this number as many expensive new hires incl execs but also terminated contracts. More sales improves bottom line as more lab capacity used. I feel it is currently heavily under capacity (probably around 20-30%)?